scholarly journals Long‐term therapeutic effect in nonhuman primate eye from a single injection of anti‐VEGF controlled release hydrogel

2019 ◽  
Vol 4 (2) ◽  
Author(s):  
Yu Yu ◽  
Xingyan Lin ◽  
Qilin Wang ◽  
Mingguang He ◽  
Ying Chau
Keyword(s):  
Controlled Release ◽  
Therapeutic Effect ◽  
Nonhuman Primate ◽  
Single Injection ◽  
Anti Vegf

Prepubertal angiotensin blockade exerts long-term therapeutic effect through sustained ATRAP activation in salt-sensitive hypertensive rats

2011 ◽  
Vol 29 (10) ◽  
pp. 1919-1929 ◽  
Author(s):  
Toru Dejima ◽  
Kouichi Tamura ◽  
Hiromichi Wakui ◽  
Akinobu Maeda ◽  
Masato Ohsawa ◽  
...  
Keyword(s):  
Therapeutic Effect ◽  
Hypertensive Rats ◽  
Angiotensin Blockade

Long-Term Efficacy of Diltiazem Controlled Release Versus Metoprolol in Patients with Stable Angina Pectoris

1991 ◽  
Vol 18 ◽  
pp. S55-S60
Author(s):  
H. W. Vliegen ◽  
E. E. van der Wall ◽  
M. G. Niemeyer ◽  
N. J. Holwerda ◽  
P. J. L. M. Bernink ◽  
...  
Keyword(s):  
Controlled Release ◽  
Angina Pectoris ◽  
Stable Angina ◽  
Stable Angina Pectoris ◽  
Term Efficacy

Results of long-term treatment with controlled-release levodopa/carbidopa (Sinemet CR)

1990 ◽  
Vol 2 (3) ◽  
pp. 205-213 ◽  
Author(s):  
J. M. Cedarbaum ◽  
M. Silvestri ◽  
M. Clark ◽  
L. Toy ◽  
A. Harts ◽  
...  
Keyword(s):  
Controlled Release ◽  
Term Treatment ◽  
Long Term Treatment

scholarly journals Shaping long-term primate development: Telomere length trajectory as an indicator of early maternal maltreatment and predictor of future physiologic regulation

2017 ◽  
Vol 29 (5) ◽  
pp. 1539-1551 ◽  
Author(s):  
Stacy S. Drury ◽  
Brittany R. Howell ◽  
Christopher Jones ◽  
Kyle Esteves ◽  
Elyse Morin ◽  
...  
Keyword(s):  
Telomere Length ◽  
Nonhuman Primate ◽  
Social Rank ◽  
Juvenile Period ◽  
Primate Model ◽  
Causal Pathways ◽  
Biological Mother ◽  
Physiologic Regulation ◽  
Negative Health Outcomes

AbstractThe molecular, neurobiological, and physical health impacts of child maltreatment are well established, yet mechanistic pathways remain inadequately defined. Telomere length (TL) decline is an emerging molecular indicator of stress exposure with definitive links to negative health outcomes in maltreated individuals. The multiple confounders endemic to human maltreatment research impede the identification of causal pathways. This study leverages a unique randomized, cross-foster, study design in a naturalistic translational nonhuman primate model of infant maltreatment. At birth, newborn macaques were randomly assigned to either a maltreating or a competent control mother, balancing for sex, biological mother parenting history, and social rank. Offspring TL was measured longitudinally across the first 6 months of life (infancy) from peripheral blood. Hair cortisol accumulation was also determined at 6, 12, and 18 months of age. TL decline was greater in animals randomized to maltreatment, but also interacted with biological mother group. Shorter TL at 6 months was associated with higher mean cortisol levels through 18 months (juvenile period) when controlling for relevant covariates. These results suggest that even under the equivalent social, nutritional, and environmental conditions feasible in naturalistic translational nonhuman primate models, early adverse caregiving results in lasting molecular scars that foreshadow elevated health risk and physiologic dysregulation.

scholarly journals Comparative strategies to induce long-term graft acceptance in fully allogeneic renal versus cardiac allograft models by CD28-B7 T cell costimulatory blockade: role of thymus and spleen.

1998 ◽  
Vol 9 (5) ◽  
pp. 891-898
Author(s):  
M Schaub ◽  
T H Stadlbauer ◽  
A Chandraker ◽  
J P Vella ◽  
L A Turka ◽  
...  
Keyword(s):  
T Cell ◽  
Species Differences ◽  
Single Injection ◽  
Maintenance Phase ◽  
Cardiac Allograft ◽  
Costimulatory Blockade ◽  
Histocompatibility Complex ◽  
Donor Cells

Blocking CD28-B7 T cell costimulatory activation by the fusion protein CTLA4Ig prevents rejection and induces long-term graft acceptance in various experimental transplant models. There are reported differences in the efficacy of CTLA4Ig in renal and cardiac rodent allograft models, but it is not clear whether these are due to the strain or species differences investigated in the different studies reported. This study investigates the effect of blocking CD28-B7 T cell costimulation with murine CTLA4Ig in rat models of acute renal and cardiac allograft rejection models, using the same complete major histocompatibility complex-incompatible strain combination. A single injection of murine CTLA4Ig 2 d after engraftment was able to induce long-term graft acceptance (> 100 d) in 54% of Lewis rat recipients of Wistar-Furth kidneys. Transferring this protocol into the acute Wistar-Furth to Lewis heart allograft model resulted in a mean graft survival time of 24.7+/-16.9 d, and all grafts were ultimately rejected. Only concomitant injection of donor cells (4 x 10(7) splenocytes) plus a single injection of CTLA4Ig on the day of transplant could induce long-term graft acceptance in 50% of animals. In both the cardiac and renal transplant models, the thymus and spleen were required for induction of tolerance. The maintenance phase of tolerance, however, did not require an intact thymus but did require the presence of a spleen. These data have important clinical applicability because human studies with T cell costimulatory blockade are being planned.

Anti-VEGF Therapy in Myopic Choroidal Neovascularization: Long-Term Results

2014 ◽  
Vol 232 (1) ◽  
pp. 57-63 ◽  
Author(s):  
Paulo Freitas-da-Costa ◽  
João Pinheiro-Costa ◽  
Beatriz Carvalho ◽  
Manuel Falcão ◽  
Elisete Brandão ◽  
...  
Keyword(s):  
Choroidal Neovascularization ◽  
Long Term Results ◽  
Myopic Choroidal Neovascularization ◽  
Anti Vegf

Long-term treatment with anti-VEGF does not induce cell aging in primary retinal pigment epithelium

2018 ◽  
Vol 171 ◽  
pp. 1-11 ◽  
Author(s):  
Johann Schottler ◽  
Niklas Randoll ◽  
Ralph Lucius ◽  
Amke Caliebe ◽  
Johann Roider ◽  
...  
Keyword(s):  
Retinal Pigment Epithelium ◽  
Pigment Epithelium ◽  
Retinal Pigment ◽  
Term Treatment ◽  
Cell Aging ◽  
Anti Vegf ◽  
Long Term Treatment

scholarly journals A novel neural prosthesis providing long-term electrocorticography recording and cortical stimulation for epilepsy and brain-computer interface

2019 ◽  
Vol 130 (4) ◽  
pp. 1166-1179 ◽  
Author(s):  
Pantaleo Romanelli ◽  
Marco Piangerelli ◽  
David Ratel ◽  
Christophe Gaude ◽  
Thomas Costecalde ◽  
...  
Keyword(s):  
Nonhuman Primate ◽  
Large Scale ◽  
Brain Activity ◽  
Threshold Value ◽  
Time Span ◽  
Cortical Stimulation ◽  
Neural Prosthesis ◽  
Lower Limbs ◽  
Custom Made

OBJECTIVEWireless technology is a novel tool for the transmission of cortical signals. Wireless electrocorticography (ECoG) aims to improve the safety and diagnostic gain of procedures requiring invasive localization of seizure foci and also to provide long-term recording of brain activity for brain-computer interfaces (BCIs). However, no wireless devices aimed at these clinical applications are currently available. The authors present the application of a fully implantable and externally rechargeable neural prosthesis providing wireless ECoG recording and direct cortical stimulation (DCS). Prolonged wireless ECoG monitoring was tested in nonhuman primates by using a custom-made device (the ECoG implantable wireless 16-electrode [ECOGIW-16E] device) containing a 16-contact subdural grid. This is a preliminary step toward large-scale, long-term wireless ECoG recording in humans.METHODSThe authors implanted the ECOGIW-16E device over the left sensorimotor cortex of a nonhuman primate (Macaca fascicularis), recording ECoG signals over a time span of 6 months. Daily electrode impedances were measured, aiming to maintain the impedance values below a threshold of 100 KΩ. Brain mapping was obtained through wireless cortical stimulation at fixed intervals (1, 3, and 6 months). After 6 months, the device was removed. The authors analyzed cortical tissues by using conventional histological and immunohistological investigation to assess whether there was evidence of damage after the long-term implantation of the grid.RESULTSThe implant was well tolerated; no neurological or behavioral consequences were reported in the monkey, which resumed his normal activities within a few hours of the procedure. The signal quality of wireless ECoG remained excellent over the 6-month observation period. Impedance values remained well below the threshold value; the average impedance per contact remains approximately 40 KΩ. Wireless cortical stimulation induced movements of the upper and lower limbs, and elicited fine movements of the digits as well. After the monkey was euthanized, the grid was found to be encapsulated by a newly formed dural sheet. The grid removal was performed easily, and no direct adhesions of the grid to the cortex were found. Conventional histological studies showed no cortical damage in the brain region covered by the grid, except for a single microscopic spot of cortical necrosis (not visible to the naked eye) in a region that had undergone repeated procedures of electrical stimulation. Immunohistological studies of the cortex underlying the grid showed a mild inflammatory process.CONCLUSIONSThis preliminary experience in a nonhuman primate shows that a wireless neuroprosthesis, with related long-term ECoG recording (up to 6 months) and multiple DCSs, was tolerated without sequelae. The authors predict that epilepsy surgery could realize great benefit from this novel prosthesis, providing an extended time span for ECoG recording.

Treatment of cystoid macular oedema secondary to pentosan polysulfate maculopathy using anti-VEGF and intravitreal steroid injections

2021 ◽  
pp. 112067212110663
Author(s):  
Samantha Roshani De Silva ◽  
Isuru De Silva ◽  
Bishwanath Pal
Keyword(s):  
Treatment Outcomes ◽  
Macular Oedema ◽  
Therapeutic Options ◽  
Cystoid Macular Oedema ◽  
Pentosan Polysulfate ◽  
Steroid Injections ◽  
Anti Vegf ◽  
Drug Cessation

Background Pentosan polysulfate-related maculopathy is a recently described clinical entity, related to dose and long term use of this medication, and may progress despite drug cessation. Cystoid macular oedema (CMO) has been reported in some cases, but there are few reports of treatment outcomes in the literature. Aims We present the case of a 55 year old female, with CMO secondary to pentosan polysulfate maculopathy, that was responsive to treatment with both intravitreal anti-VEGF and steroid injections, stabilising vision over a four year follow up period. Conclusions This is the first report, to our knowledge, of CMO related to pentosan polysulfate maculopathy responding to intravitreal steroid injections, broadening the therapeutic options for preserving vision in these patients.

Long-term outcome of neovascular age-related macular degeneration: association between treatment outcome and major risk alleles

2021 ◽  
pp. bjophthalmol-2021-319054
Author(s):  
Brice Nguedia Vofo ◽  
Gala Beykin ◽  
Jaime Levy ◽  
Itay Chowers
Keyword(s):  
Macular Degeneration ◽  
Vision Loss ◽  
Age Related Macular Degeneration ◽  
Long Term Outcome ◽  
Risk Alleles ◽  
Macular Atrophy ◽  
Anti Vegf ◽  
Age Related

AimsTo evaluate the long-term functional and anatomical outcomes of neovascular age-related macular degeneration (nvAMD) treated with intravitreal anti-vascular endothelial growth factor (anti-VEGF) for up to 10 years, and to identify associated risk factors.MethodsClinical and optical coherence tomography findings were retrieved for nvAMD cases treated with intravitreal anti-VEGF compounds using a treat-and-extend protocol. In addition, the major risk alleles for AMD in the CFH (rs1061170), HTRA1 (rs1200638) and C3 (rs2230199) genes were genotyped.ResultsFrom 276 eligible eyes in 206 patients, 80 eyes (29%) in 66 patients (32.0%) had a follow-up period of ≥8 years and were included in this study. Over a 10-year period, 73.3±28.0 (mean±SD) anti-VEGF injections were administered. Best-corrected visual acuity (BCVA; LogMAR) deteriorated from 0.55±0.53 at baseline to 1.00±0.73 at 10 years (p<0.0005). Central subfield thickness (CST) decreased from 415.8±162.1 µm at baseline to 323±113.6 µm (p<0.0005) after three monthly injections and remained lower than baseline throughout the follow-up period. Visual outcome was associated with BCVA and intraretinal fluid (IRF) at baseline, macular atrophy, and macular thinning at follow-up. The decrease in CST was inversely correlated with the number of CFH and/or C3 risk alleles carried by the patient (Pearson’s r: −0.608; p=0.003).ConclusionsPatients with nvAMD who received anti-VEGF therapy for 10 years developed substantial vision loss associated with the presence of IRF at baseline and macular atrophy. Major risk alleles for AMD in two complement genes were associated with a reduced long-term reduction in macular thickness.

Sign in / Sign up

Export Citation Format

Share Document